1. Feasibility of using phenylacetylpyridadiene, dwarf or salt derivatives with acceptable pharmacodynamics to reduce the number of multicellular cells to IL-6 and/or CD45 phenol in non-sclerosing cells.
BURNS CHRISTOPHER JOHN,SPENCER ANDREW,MONAGHAN KATHERINE ANNE
申请号：
CL2013003143
公开号：
CL2013003143A1
申请日:
2013.10.30
申请国别(地区):
CL
年份:
2014
代理人:
摘要：
A method of treating a subject presenting with multiple myeloma at a stage characterized by an increase in the prevalence of MM cells that (1) are IL-6 non-responsive and/or (2) have a CD45&minus； phenotype, comprising administering to the subject an amount of a compound of formula Ib.USO DE COMPUESTOS DERIVADOS DE FENILAMINOPIRIMIDINILO, UN ENANTIOMERO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO PARA REDUCIR LA VIABILIDAD DE CELULAS DE MIELOMA MULTIPLE EN UN ESTADO DE CELULAS NO ERSPONDEDORAS A IL-6 Y/O QUE TIENEN UN FENOTIPO CD45-.
